Institutional members access full text with Ovid®

Share this article on:

Guiding in the Face of Minimal Evidence: A Strength, Not a Weakness, of Graded Clinical Practice Guidelines

File, Thomas M. Jr MD

Infectious Diseases in Clinical Practice: May 2010 - Volume 18 - Issue 3 - p 151
doi: 10.1097/IPC.0b013e3181dce63d

From the Northeastern Ohio Universities College of Medicine and Pharmacy, Rootstown and Summa Health System, Akron, OH.

Reprints: Thomas M. File Jr, MD, 75 Arch St, Suite 506, Akron, OH 44304. E-mail:

The author discloses that he has received recent research funding from Cerexa/Forest, Ortho-McNeil, Pfizer, Boehringer Ingelheim, Gilead, and Tibotec and is a consultant for Cerexa/Forest, Ortho-McNeil, Protez, Merck, Nabriva, and Pfizer.

© 2010 Lippincott Williams & Wilkins, Inc.